Merck-Medco
Executive Summary
Michael Atieh to Exec VP Merck-Medco U.S. Managed Care Division, from Merck VP-public affairs. Atieh, 40, is assuming the second spot in the management hierarchy of the combined sales operation formed from the Merck-Medco merger last year. Senior Medco exec Per Lofberg was put in charge of the managed care division when it was formed at the beginning of this year. The appointment of Atieh, who was Merck's liaison to the investment community in the mid-1980's, may help reassure the financial community about the changes in the profit formulas at Merck. Traditional pharmaceutical industry analysts have been reluctant about accepting the prospects for the company. Comments about low margins by Medco execs at a major meeting with the financial community earlier this year did not sweeten the relationship
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth